About Us
People, Science, and Purpose Behind PHP Biotech
Our Story
An introduction to PHP Biotech
Our journey began with a simple but ambitious goal: to develop better treatment options for people facing the most aggressive and difficult-to-treat cancers.
By working closely with leading research laboratories, we discovered two key innovations—a novel p53-reactivating peptide, 3-NAntC, and a humanized camelid nanobody delivery platform, GEN01-AD. Together, they form PHP53-nb, a therapeutic designed to selectively target tumor cells and restore p53’s natural tumor-suppressing function.
Getting here took time, persistence, and careful science. We spent more than 5 years screening and refining peptide candidates, followed by two years developing and scaling the GEN01-AD platform. The result is PHP53-nb, which has shown encouraging results in TNBC and other aggressive cancer types, including pancreatic cancer.
Importantly, this work goes beyond a single therapy. PHP53-nb offers opportunities for combination and future multi-specific approaches, while GEN01-AD provides a flexible platform for delivering other peptide therapeutics — helping us build a pipeline focused on precision, innovation, and patient impact.
Our Journey
Year 1–5
Peptide Discovery & Screening
More than 5 years screening and refining p53-reactivating peptide candidates, leading to the discovery of 3-NAntC.
Year 6–7
GEN01-AD Platform Development
Two years designing and scaling the humanized camelid nanobody delivery platform to enable stable, linker-free peptide delivery.
Year 8
PHP53-nb: Lead Candidate Emerges
PHP53-nb demonstrates encouraging preclinical results in TNBC and other aggressive cancer types.
2026
Pre-Clinical Studies
Planned completion of pre-clinical studies.
2027
Clinical Trials
Anticipated start of Phase I clinical trials.
Leadership Team
PHP Biotech’s leadership team brings together expertise in oncology, biotech operations, finance, and scientific research — all united by a commitment to improving outcomes for cancer patients.
About RobertRobert Gahagen
CEO
Chief Executive Officer
Get to know Robert
- About Eduardo
Eduardo Motti, MD
COO
Chief Operating Officer
Get to know Eduardo
- About Joao
Joao Marcelo Carucci
CFO
Chief Financial Officer
Get to know Joao
- About Patrícia
Patrícia Bezerra, PhD
Scientific Leader
Head of Research & Development
Get to know Patrícia
Executive Committee
The Executive Committee provides strategic oversight and direction for PHP Biotech’s operations, partnerships, and long-term vision.
- About Moacyr
Moacyr Bighetti
Founder
Co-Founder & Executive Committee
Get to know Moacyr
- About Oswaldo
Oswaldo Bighetti
Executive Committee Member
Get to know Oswaldo
- About Eduardo
Eduardo Braun, MD
Executive Committee Member
Get to know Eduardo
- About Paulo
Paulo Nigro
Executive Committee Member
Get to know Paulo
Advisory Board
PHP Biotech’s Advisory Board consists of distinguished clinicians, oncologists, and scientists who provide expert guidance on the development and clinical translation of our therapies.
- About Antonio
Antonio Carlos Buzaid, MD
Advisory Board Member
Get to know Antonio
- About Fabio
Fabio Jung, MD
Advisory Board Member
Get to know Fabio
- About Jorge
Jorge Brasil, MD
Advisory Board Member
Get to know Jorge
- About Kleber
Kleber Miranda
Advisory Board Member
Get to know Kleber
